Discussion  by unknown
Ideally, randomized controlled trials comparing endo-
vascular ablation with open reconstruction are required to
make firm recommendations for protocols of therapy.
Given the paucity of visceral artery aneurysms, however, the
distinct behavior between aneurysms of different visceral
vessels and the malignant natural history of pseudoaneu-
rysms, such studies would likely be not be realistic or
fulfilling. Longer-term follow-up with larger patient co-
horts are necessary to elucidate the ultimate role of endolu-
minal therapy in the treatment of visceral artery aneurysms
and pseudoaneurysms.
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DISCUSSION
Dr Paul Van Bemmelen (Philadelphia, Pa). Did you rule out
mycotic aneurysms in this population? Were there any comparable
open treatments done during this time period, or is everybody
treated endovascularly?
Dr Nirman Tulsyan. During the study period, we identified
90 patients with visceral artery aneurysms. Nineteen patients un-
derwent open treatment. The choice of therapeutic modality was
primarily operator-dependent given the retrospective nature of this
paper. Of the patients who presented with true aneurysms, none
clinically manifested prodromal symptoms or signs to suggest
presence of a mycotic aneurysm or microbial arteritis with aneu-
rysmal degeneration.
With respect to the pseudoaneurysms, the majority of patients
presented with signs of systemic inflammation, whether that be
intra-abdominal sepsis or retroperitoneal inflammation. While it is
possible that these lesions were mycotic, we did not make the
distinction nor did it change our management.
Dr Grayson Wheatley (Phoenix, Ariz). How do you ap-
proach visceral artery aneurysms with respect to embolization
versus excluding with an endoluminal graft? I would think that
some of these visceral aneurysms would be amenable to exclusion
rather than embolization.
Dr Tulsyan. Subsequent to the end of the study period, we’ve
actually treated multiple patients with stent grafts in an effort to
maintain parent artery patency. With regard to true aneurysms, we
have noted that use of stent grafts is a function of the location of the
aneurysm. In the setting of a splenic artery aneurysm, for example,
distal, hilar, or intrasplenic lesions would be technically difficult to
treat with currently available stent grafts.
Additionally, we have noted a significant amount of elonga-
tion and tortuosity of parent arteries that occurs in the setting of
visceral artery aneurysms. In attempting to treat a distal vessel it
may be difficult to deliver your device. It may be feasible, however,
in the setting of more proximal lesions.
Dr. Robert Cambria (Bangor, Me). Several small series have
indicated association of stenosis of major visceral vessels with
pseudoaneurysms or, rather, true aneurysms of the visceral seg-
ments. Did you notice this association and did it impact in any way
on your approach? And finally, were there any aneurysms that you
attempted to treat but could not?
Dr Tulsyan. In reviewing all of the imaging, we actually did
not find a high incidence of aortoiliac occlusive disease. As such,
this did not alter our treatment.
There was one technical failure in our series. This occurred in
a patient who underwent successful treatment of a celiac axis
aneurysm but had persistent flow within the celiac trunk after
embolization. On follow-up imaging, there was a decrease in aneu-
rysm size. However, since there was significant flow on completion
angiography, a secondary intervention was performed via the SMA.
Dr Kenneth Cherry (Charlottesville, Va). When you have an
aneurysm that involves either the SMA or one of its major
branches, are you at all hesitant about providing an occlusive
solution as opposed to one that insures continued patency?
Dr Tulsyan. All the patients in our study with mesenteric
aneurysms were treated for lesions of branch vessels. We would be
very hesitant to ablate a main trunk aneurysm of the SMA, for
example, since the risk and sequelae of end-organ ischemia is
significant in this situation. We would elect for alternative therapy
in this instance.
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